The Herschel view of circumstellar discs: a multi-wavelength study of Chamaeleon I

We present the results of a multi-wavelength study of circumstellar discs around 44 young stellar objects in the 3 Myr old nearby Chamaeleon I star-forming region. In particular, we explore the far-infrared/submm regime using Herschel fluxes. We show that Herschel fluxes at 160-500$\,\mu$m can be used to derive robust estimates of the disc mass. The median disc mass is 0.005$M_{\odot}$ for a sample of 28 Class IIs and 0.006$M_{\odot}$ for 6 transition disks (TDs). The fraction of objects in Chamaeleon-I with at least the `minimum mass solar nebula' is 2-7%. This is consistent with previously published results for Taurus, IC348, $\rho$ Oph. Diagrams of spectral slopes show the effect of specific evolutionary processes in circumstellar discs. Class II objects show a wide scatter that can be explained by dust settling. We identify a continuous trend from Class II to TDs. Including Herschel fluxes in this type of analysis highlights the diversity of TDs. We find that TDs are not significantly different to Class II discs in terms of far-infrared luminosity, disc mass or degree of dust settling. This indicates that inner dust clearing occurs independently from other evolutionary processes in the discs.Comment: 16 pages, 13 figures. Accepted for publication in MNRA

Gone with the breeze: A subsonic outflow solution to the Fermi bubbles problem

The origin of the Fermi bubbles, which constitute two gamma-rays emitting lobes above and below the Galactic plane, remains unclear. The possibility that the Fermi bubble gamma-rays emission originates from hadronic cosmic-rays advected by a subsonic Galactic outflow is explored. Such a solution is called a Galactic breeze. This model is motivated by UV absorption line observations of cold clouds expanding from the Galactic center to high latitudes. For this purpose the hydrodynamical code PLUTO has been used in combination with a cosmic ray transport code. A model of the Galactic gravitational potential has been determined through constraints derived from the Gaia second data release. It is found that a Galactic breeze can be collimated by the surrounding gas and is indeed able to reproduce the observed Fermi-LAT energy flux at high Galactic latitudes. Following these results a prediction concerning the gamma-rays emission for 1-3~TeV photons is made for future comparison with CTA/SWGO measurements

Stellar versus galactic: the intensity of cosmic rays at the evolving earth and young exoplanets around sun-like stars

Energetic particles, such as stellar cosmic rays, produced at a heightened rate by active stars (like the young Sun) may have been important for the origin of life on Earth and other exoplanets. Here, we compare, as a function of stellar rotation rate (ω), contributions from two distinct populations of energetic particles: stellar cosmic rays accelerated by impulsive flare events and Galactic cosmic rays. We use a 1.5D stellar wind model combined with a spatially 1D cosmic ray transport model. We formulate the evolution of the stellar cosmic ray spectrum as a function of stellar rotation. The maximum stellar cosmic ray energy increases with increasing rotation, i.e. towards more active/younger stars. We find that stellar cosmic rays dominate over Galactic cosmic rays in the habitable zone at the pion threshold energy for all stellar ages considered (t_∗=0.6-2.9 Gyr). However, even at the youngest age, t_∗=0.6 Gyr, we estimate that ≳, 80 MeV stellar cosmic ray fluxes may still be transient in time. At ∼1 Gyr when life is thought to have emerged on Earth, we demonstrate that stellar cosmic rays dominate over Galactic cosmic rays up to ∼4 GeV energies during flare events. Our results for t∗ = 0.6 Gyr (ω = 4 ω·) indicate that GeV stellar cosmic rays are advected from the star to 1 au and are impacted by adiabatic losses in this region. The properties of the inner solar wind, currently being investigated by the Parker Solar Probe and Solar Orbiter, are thus important for accurate calculations of stellar cosmic rays around young Sun-like stars

Stellar cosmic rays as an important source of ionization in protoplanetary discs: a disc mass-dependent process

We assess the ionizing effect of low-energy protostellar cosmic rays in protoplanetary discs around a young solar mass star for a wide range of disc parameters. We assume a source of low-energy cosmic rays located close to the young star that travels diffusively through the protoplanetary disc. We use observationally inferred values from nearby star-forming regions for the total disc mass and the radial density profile. We investigate the influence of varying the disc mass within the observed scatter for a solar mass star. We find that for a large range of disc masses and density profiles that protoplanetary discs are ‘optically thin’ to low-energy (∼3 GeV) cosmic rays. At R ∼ 10 au, for all of the discs that we consider (Mdisc = 6.0 × 10−4– 2.4 × 10−2M), the ionization rate due to low-energy stellar cosmic rays is larger than that expected from unmodulated galactic cosmic rays. This is in contrast to our previous results that assumed a much denser disc that may be appropriate for a more embedded source. At R ∼ 70 au, the ionization rate due to stellar cosmic rays dominates in ∼50 per cent of the discs. These are the less massive discs with less steep density profiles. At this radius, there is at least an order of magnitude difference in the ionization rate between the least and most massive disc that we consider. Our results indicate, for a wide range of disc masses, that low-energy stellar cosmic rays provide an important source of ionization at the disc mid-plane at large radii (∼70 au)

MINDS. Abundant water and varying C/O across the disk of Sz 98 as seen by JWST/MIRI

MIRI/MRS on board the JWST allows us to probe the inner regions of protoplanetary disks. Here we examine the disk around the classical T Tauri star Sz 98, which has an unusually large dust disk in the millimetre with a compact core. We focus on the H$_2$O emission through both its ro-vibrational and pure rotational emission. Furthermore, we compare our chemical findings with those obtained for the outer disk from Atacama Large Millimeter/submillimeter Array (ALMA) observations. In order to model the molecular features in the spectrum, the continuum was subtracted and LTE slab models were fitted. The spectrum was divided into different wavelength regions corresponding to H$_2$O lines of different excitation conditions, and the slab model fits were performed individually per region. We confidently detect CO, H$_2$O, OH, CO$_2$, and HCN in the emitting layers. The isotopologue H$^{18}_2$O is not detected. Additionally, no other organics, including C$_2$H$_2$, are detected. This indicates that the C/O ratio could be substantially below unity, in contrast with the outer disk. The H$_2$O emission traces a large radial disk surface region, as evidenced by the gradually changing excitation temperatures and emitting radii. The OH and CO$_2$ emission are relatively weak. It is likely that H$_2$O is not significantly photodissociated; either due to self-shielding against the stellar irradiation, or UV-shielding from small dust particles. The relative emitting strength of the different identified molecular features point towards UV-shielding of H$_2$O in the inner disk of Sz 98, with a thin layer of OH on top. The majority of the organic molecules are either hidden below the dust continuum, or not present. In general, the inferred composition points to a sub-solar C/O ratio (<0.5) in the inner disk, in contrast with the larger than unity C/O ratio in the gas in the outer disk found with ALMA.Comment: Submitted to A&A on May 25 2023. 18 pages, 11 figure

MINDS. The detection of 13^{13}CO2_{2} with JWST-MIRI indicates abundant CO2_{2} in a protoplanetary disk

We present JWST-MIRI MRS spectra of the protoplanetary disk around the low-mass T Tauri star GW Lup from the MIRI mid-INfrared Disk Survey (MINDS) GTO program. Emission from $^{12}$CO$_{2}$, $^{13}$CO$_{2}$, H$_{2}$O, HCN, C$_{2}$H$_{2}$, and OH is identified with $^{13}$CO$_{2}$ being detected for the first time in a protoplanetary disk. We characterize the chemical and physical conditions in the inner few au of the GW Lup disk using these molecules as probes. The spectral resolution of JWST-MIRI MRS paired with high signal-to-noise data is essential to identify these species and determine their column densities and temperatures. The $Q$-branches of these molecules, including those of hot-bands, are particularly sensitive to temperature and column density. We find that the $^{12}$CO$_{2}$ emission in the GW Lup disk is coming from optically thick emission at a temperature of $\sim$400 K. $^{13}$CO$_{2}$ is optically thinner and based on a lower temperature of $\sim$325 K, may be tracing deeper into the disk and/or a larger emitting radius than $^{12}$CO$_{2}$. The derived $N_{\rm{CO_{2}}}$/$N_{\rm{H_{2}O}}$ ratio is orders of magnitude higher than previously derived for GW Lup and other targets based on \textit{Spitzer}-IRS data. This high column density ratio may be due to an inner cavity with a radius in between the H$_{2}$O and CO$_{2}$ snowlines and/or an overall lower disk temperature. This paper demonstrates the unique ability of JWST to probe inner disk structures and chemistry through weak, previously unseen molecular features.Comment: 15 pages, 10 figures. Accepted to ApJ

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention